Tolero Pharmaceuticals Bumps Series B To $22.4M

Salt Lake City-based biopharmaceuticals developer Tolero Pharmaceuticals has increased the company's Series B funding round, saying the company has now raised a total of $22.4M. The developer of treatments for oncology and hematologic diseases said the round was led by Fred Alger Management, along with other, un-named investors. The company said the funding will go towards advancement of its lead program, alvocidib, which is aimed at treating acute myeloid leukemia (AML). Tolero Pharmaceuticals is led by Dr. David Bearss.